文献速递腹部USMRCT

与临床可干预的高回声肝脏病灶相关的特征,以确定是否需要随访

Features associated with clinically actionable hyperechoic hepatic lesions to determine the need for follow-up.
PubMed 文献 · Abdom Radiol (NY) · 2024-07-10

回顾性分析228例超声高回声肝脏病灶,14例(6.1%)为临床可干预病灶,214例(93.9%)无临床意义。多因素分析显示年龄、肝硬化病史和病灶大小是预测可干预病灶的特征。无恶性肿瘤或基础肝病且病灶≤3 cm者100%(168/168)无临床意义。

要点

  • 超声高回声肝病灶中仅6.1%(14/228)为临床可干预,多数无临床意义。
  • 年龄、肝硬化病史和病灶大小是可干预高回声肝病灶的预测特征。
  • 无恶性肿瘤或基础肝病者≤3 cm高回声病灶100%(168/168)无临床意义。

核心结论

  • 研究结果支持无基础风险因素患者中≤3 cm的高回声肝脏病灶总体为良性诊断。

研究设计与样本

  • 回顾性研究纳入228例患者共228个超声高回声肝脏病灶;参考标准为动态增强MRI(n=130)、CT(n=46)、至少2年随访超声(n=50)或组织病理学(n=2);三位放射科医师独立评估影像特征。

关键影像表现/征象

  • 病灶回声不均匀在可干预组为50%,无临床意义组为16.4%(p=0.006)。
  • 背景肝呈肝硬化/粗糙回声在可干预组为35.7%,无临床意义组为7.5%(p=0.005)。

诊断标准与关键数值

  • 可干预病灶的预测特征:年龄(OR 1.04)、肝硬化病史(OR 24.3)、病灶大小(OR 1.77)。
  • 影像特征读者一致性为一般至中等(k=0.29-0.53)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate the rate of hyperechoic liver lesions that are clinically actionable and evaluate imaging and clinical factors associated with these to determine the need for follow-up.

MATERIALS AND METHODS: This retrospective study included 228 hyperechoic hepatic lesions on ultrasound in 228 patients. Reference standards included either dynamic contrast enhanced MRI (n = 130) or CT (n = 46), follow-up ultrasound performed at least 2 years from baseline (n = 50), or histopathology (n = 2). Three radiologists independently assessed imaging features including lesion orientation, degree of hyper-echogenicity, lesion heterogeneity, and background liver echotexture. Univariable and multivariable logistic regression was used to determine features associated with an actionable hyperechoic lesion.

RESULTS: Of the 228 hyperechoic lesions, 14 (6.1%) lesions were clinically actionable (or requiring follow-up), and 214 (93.9%) were clinically insignificant. Features that differed between patients with clinically insignificant vs. actionable lesions included: age (52.9 ± 15.1 vs. 63.9 ± 15.8 years, p = 0.004), male sex (43.9% vs 71.4%, p = 0.045), history of cirrhosis (6.5% vs 50%, p < 0.001), lesion size (1.9 ± 1.4 cm vs. 3.5 ± 2.8 cm, p = 0.003), heterogeneous lesion echogenicity (16.4% vs. 50%, p = 0.006), and cirrhotic/coarsened background liver (7.5% vs. 35.7%, p = 0.005). Stepwise logistic regression and multivariable analysis identified age, presence of cirrhosis, and lesion size as features most predictive of an actionable lesion (OR 1.04, 24.3, 1.77 respectively). Reader agreement for imaging features was fair to moderate (k = 0.29-0.53). 100%(168/168) of hyperechoic liver lesions measuring ≤ 3 cm in patients without a history of malignancy or underlying liver disease were clinically insignificant.

CONCLUSION: Our study findings support the overall favorable diagnoses of hyperechoic liver lesions ≤ 3 cm in patients without underlying risk factors.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Li K, Chen H, Gavlin A, et al. Features associated with clinically actionable hyperechoic hepatic lesions to determine the need for follow-up. Abdom Radiol (NY). 2024. PMID: 38987400. doi:10.1007/s00261-024-04248-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。